Clinical efficacy and the influence of fibrinogen, homocysteine and prognosis in acute ischemic stroke patients treated with tirofiban plus TERVO stent thrombectomy.

To evaluate the clinical efficacy and the influence of fibrinogen, homocysteine and prognosis in acute ischemic stroke (AIS) treated with tirofiban plus TERVO stent thrombectomy. A retrospective study was conducted among 82 patients with AIS admitted to the Department of Neurology in Hengshui People's Hospital from December 2018 to December 2020 and they were evenly divided into control group and study group according to different methods. The control group received TERVO stent thrombectomy; the study group received tirofiban plus. The clinical efficacy, modified thrombolysis in cerebral infarction (mTICI) grade, serum levels of fibrinogen and homocysteine, National Institute of Health stroke scale (NIHSS), and activity of daily living (ADL) scores were compared. Significant higher clinical efficacy was observed in the study group vs. control group (all p<0.05). The study group witnessed lower percentage of 0~1 grade of mTICI blood flow in relative to the control group (all p<0.05). After treatment, significant reduction was observed in FIB and HCY in both groups, but the treatment in the study group resulted in a greater reduction (all p<0.05). After treatment, both groups reported a significant increase in NIHSS score and ADL score, with more increase in the study group (all p<0.05). The safety profiles were similar in the two groups with respect to the adverse reactions (p>0.05). Tirofiban plus TERVO stent thrombectomy could improve vascular recanalization rate, reduce fibrinogen and homocysteine levels and improve short-term prognosis in AIS patients.